Transcript GE2 Flow and Image Cytometry webinar on 31 Oct 2012 Flow … · a flow cytometry, but...
Transcript of Transcript GE2 Flow and Image Cytometry webinar on 31 Oct 2012 Flow … · a flow cytometry, but...
1
What Cytometry Can Do for You: The Pros and Cons of Image and Flow Cytometry
Webinar 31 October 2012
[0:00:10] Slide 1 Sean Sanders: Hello everyone and welcome to this Science/AAAS webinar. I’m Sean
Sanders, editor for custom publishing at Science. Today’s webinar will be about all things cytometric. Flow cytometry
has been used for decades as the method of choice to gather valuable data on an individual cell level. More recently, image cytometry technologies including high‐content analysis have emerged to enable more detailed cellular and subcellular analysis, particularly of adherent cell types. Image cytometry has become less expensive and more accessible, giving experts and non‐experts alike fast and easy access to detailed data about their cells.
In this webinar, our esteemed speakers will share their views on the
pros and cons of image and flow cytometry and how these technologies might be applied to their own research. It’s my pleasure to introduce my studio guests for today. They are Dr. Bill Telford from the NIH in Bethesda, Maryland, Dr. Paul Gokhale from the University of Sheffield in the United Kingdom, and Dr. Liz Roquemore from GE Healthcare based in Cardiff in the UK. A very warm welcome to you all. Thanks for being here.
Dr. Bill Telford: Thank you, Sean. Dr. Liz Roquemore: Thank you. Pleasure to be here. Sean Sanders: You will notice that Dr. Gokhale is not actually with us in the studio
today. Due to the big storm on the east coast of the US, his flight over was unfortunately cancelled, but we are very pleased that he could join us through an audio linkup. So welcome to you, Dr. Gokhale.
Dr. Paul Gokhale: It’s good to be here, Sean. Thank you.
2
Sean Sanders: Before we get started, I have some important information for our audience. Note that you can resize or hide any of the windows in your viewing console. The widgets at the bottom of the console control what you see. Click on these to see the speaker bios additional information about technologies related to today's discussion, or to download a PDF of the slides.
Each of our speakers will talk briefly about their work. After which
we will have a Q&A session during which our guests will address the questions submitted by our live online viewers. So if you're joining us live, start thinking about some questions right now and submit them at any time by typing them into the box on the bottom left of your viewing console and clicking the submit button. If you can't see this box, just click the red Q&A widget at the bottom of the screen. Please remember to keep your questions short and concise. This will give them the best chance of being put to our panel.
You can also log in to your Facebook, Twitter, or LinkedIn accounts
during the webinar to post updates or send tweets about the event, just click the relevant widgets at the bottom of the screen. For tweets, you can add the hash tag, #sciencewebinar.
Finally, thank you to GE Healthcare for sponsoring today's webinar. Slide 2 Now, I'd like to introduce our first speaker, Dr. Bill Telford. Dr.
Telford is currently the director of the flow cytometry core laboratory in the NCI Experimental Transplantation and Immunology Branch at the NIH. His main research interests include instrument development, particularly in the area of novel solid state laser integration into flow cytometers, flow cytometric stem cell detection and characterization, and functional characterization of early apoptosis by flow and image cytometry. Welcome, Dr. Telford.
Dr. Bill Telford: Thank you, Sean, for having me here today. Slide 3 Okay. So what I’d like to do in the next few minutes is give a brief
overview of just a review of flow cytometry for those who need it and also to talk a little bit about image cytometry, which is proven to be an important adjunct technique to flow cytometry.
Slide 4
3
I think many people in our audience are aware of what goes into a traditional flow cytometer. You need first a biological sample, usually labeled with some sort of fluorescent marker. You need to move these cells in a linear stream through a focused light source, usually a laser, it doesn’t have to be but it usually is. You then need to detect the fluorescence in a PMT with a filter and then you need to process that data out the other side.
Slide 5 So this is what the data ends up looking like and when we do flow
cytometry, we’re generally analyzing three major applications and I’ll go through them one at a time. The first is fluorescent probes for cell surface or intracellular labeling usually using an antibody that’s tagged with a fluorescent marker like fluorescein or PE. Here, we’ve labeled mouse T‐cells for fast expression and CD8 expression using two fluorescent probes, FITC and PE. What I want to point out and I think this is obvious for many people who are familiar with flow but remember that all of this data is inter‐relational so that we can look at the cells that are CD8 positive in this star plot over here on the right and look at the Fas expression within those cells and also the Fas expression in the CD8 negative cells as well. Now this technology has become quite powerful. We can do 14, 26 parameter flow cytometry and the inter‐relational nature of it gives us tremendous power.
[00:05:01] Slide 6 Here, we’re looking at lymphoctyes and monocytes and
macrophages based on their forward and side scatter and we’re able to look at the expression of numerous markers based on the ability to gate on one parameter and view another. All parameters are inter‐relational relative to the other parameters.
Slide 7 Fluorescent proteins is probably the second most popular
application for flow cytometry now. This started with GFP back in the mid‐‘90s. There are now literally hundreds of fluorescent proteins that span the visible spectrum and this is another major application for flow cytometric analysis.
Slide 8 Finally, we have a large variety of physiological fluorescent probes
that can measure the physiological state of a cell. We can look at the mitochondrial membrane potential, the plasma membrane potential. We can visualize mitochondria, look at DNA content. The
4
number of probes available of this type literally are in the hundreds right now and another common application for flow cytometry.
Slide 9 However, traditional flow has its limits. We’re basically analyzing
cells that are flying through a laser beam at about 10 meters/second and all we’re generally able to do in that format is measure the total fluorescence of the cell as it passes through. We’re not getting any subcellular data. We’re able to look at the area, the width of the pulse, the height of the pulse here as the cell goes through. But generally the information we’re getting per cell is very, very limited. It’s just total fluorescence.
This is where image cytometry comes in. Image cytometry has
allowed us to actually visualize the cell and collect cytometric data at the same time. So we’re collecting the same data that we would with a flow cytometry, but we’re also able to get a picture, an image of the cell and various aspects of that image can become parameters just like fluorescence or forward scatter is a parameter.
Another key characteristic of image cytometry is that the image and
the cytometric data are correlated with each other. So you can look at a dot plot in a histogram and go back and see what that cell actually is.
Slide 10 So this is what a typical image cytometer looks like. This is a
Compycyte iCys instrument. You can see a lot of the components are pretty much exactly the same as you’d find on a flow cytometer. You’ve got lasers, you’ve got mirrors, dichroics, and filters. You’ve got photomultiplier tubes for detecting that data. But rather than the data coming from cells in a stream, it’s now coming from cells sitting on a slide or on a horizontal surface. The cells are static, they’re not moving. Now we often refer to this type of analysis as high content analysis because we’re getting more than just raw fluorescent data here. We’re actually getting data pertaining to the interior structure of the cell.
Slide 11 Another key aspect of image cytometry is that like flow cytometry it
is event thresholded or event based. On a flow cytometer, a cell will go flying for the beam. You’ll use a characteristic like forward scatter to determine whether an object is there or not and then you’ll take fluorescence and other measurements off that cell. We do exactly
5
the same thing in image cytometry. We set a parameter, it can be scatter, it can be fluorescence to identify whether cells are present. The instrument will then segment or select that object as it has in these scans here and then the cytometric data is taken. So we have both image data, cytometric data and the two are correlated with one another.
Slide 12 It can be really quite powerful and the imagery can be quite
dramatic. These are mouse lymphoma cells that have been induced to undergo apoptosis using a drug, using camptothecin. We’ve labeled them with three apoptotic markers, a caspase substrate labeled with fluorescein, Annexin V labeled with a red dye, Alexa Fluor 647 plus 7‐AAD. We’re able to get the image data and we’re able to see the presence of Annexin V labeling or caspase activation in the cells.
These images here are not photographs. They are actual PMT
reconstructed data and this PMT reconstructed data, this image data is the data by which the cytometric data is then derived. You can see the cytometric data on the right‐hand side of the slide looking very much like you would see off of a traditional flow cytometry but you’ve got the image data as well.
Slid 13 Now you can do a lot of very powerful things with this. We can look
at the subcellular structure of a cell and express that structure as a fluorescent parameter. Here, we’ve taken U2OS cells. This is a human osteosarcoma line that’s been transfected with a GFP‐LC3 fusion protein. The LC3 protein during autophagy segregates into these very tight, punctate regions. It’s normally distributed evenly throughout the cell. We can measure those punctate regions using image cytometry and express them as a parameter. So we’re not just taking total fluorescence here, we’re looking at the fluorescence structure of something inside the cell.
[00:10:24] Slide 14 Now there are a number of good image cytometer systems out
there. This is a sampling of them. I’ve shown you some data on the Compycyte iCys. The BD Biosciences Pathway systems, the 450 and the 850 work very well in this regard. The GE IN Cell platforms, the 2000 and the 6000, the Cellomics and PerkinElmer systems as well. These are generally very sophisticated systems. They can collect many fluorescent parameters. They often have multiple excitation
6
lines either lasers or lamps. They archive the data and the data can be brought up later and correlated with the cytometric data.
Slide 15 There is one stream‐based image cytometer system available. It’s
the Amnis ImageStream. Rather than capturing images with cells that are sitting on a slide or on a flat surface, this instrument actually captures the images in the stream. Here we have I believe these Raji cells that have been again labeled with multiple apoptotic markers, caspase, Annexin V and DNA and you can see brightfield and also the individual fluorescent data and this data can also be expressed cytometrically as dot plots and histograms.
Slide 16 Finally, there are a number of special purpose image cytometers out
there currently. The GE Life Sciences Cytell is one of these, the TTL Labtech Accumen, the Cytellect Celigo, the Beckman‐Coulter Vi‐cell. These instruments generally do not archive the data, but they use the data, the image data as the basis for the cytometric data they display. These systems are often designed for specialty or specific applications like viability apoptosis or basic immunolabeling. The imagery is generally not archived but sometimes intracellular features can still be quantified and these systems also distinguish themselves in generally being of lower cost than the more sophisticated systems. So they’re very good for specialty applications. They can also have very rapid throughput for applications where you need to run large numbers of samples very quickly and Dr. Gokhale will talk about that in a few minutes.
So I will conclude my talk at that point. Slide 17 Sean Sanders: Great. Dr. Bill Telford: And give it back to Sean. Sean Sanders: Thank you so much, Dr. Telford. Our second speaker for today is Dr.
Paul Gokhale. Dr. Gokhale is currently a research associate at the University of Sheffield. Over the past seven years, he has been involved in the international stem cell initiative first to develop standards to characterize human embryonic stem cells and second to identify common genetic changes that occur when human ES cells are cultured in vitro. More recently, Dr. Gokhale has been involved in projects to use real‐time imaging and image analysis to understand
7
how human embryonic stem cells self‐renew and how early differentiation decisions are controlled. Welcome, Dr. Gokhale.
Slide 18 Dr. Paul Gokhale: Okay. Thank you very much, Sean. So in my short presentation, I’m
going to take you through a brief overview of high content analysis, briefly talk about why it fits in with other cytological techniques that people are familiar with, some of the types of assays we commonly use with these systems, some factors to think about on the pros and cons compared with flow cytometry. Then I’ll go through examples of how we do the segmentation analysis so you can see how all this fits together.
Slide 19 Okay. So where does high content analysis fit in the scheme of the
sort of cell biological techniques? Well it fits really in between flow cytometry on the one hand which has very, very good throughputs and stats for generating signal cell data and the data analysis is very well refined over decades now. At the other end of the spectrum is the conventional microscopy, which is quite labor intensive, you get fantastic data, but it’s not very good for looking at large numbers of cells and large numbers of conditions.
Slide 20 So what assay do we really use high content for? Well there’s quite a
range now and it gets bigger all the time. So we’ve got things like morphology so we can stain the samples for morphology for example with phalloidin to look at the actin cytoskeleton. We can look for things like blebbing. People look at neurite outgrowth and how neurons are branching, differentiation because of the cells change shape when they differentiate typically. The fluorescent intensity type measures, which is probably the one you would guess we would use it for which things like cell cycle, for marker expression, which is very similar to the flow cytometric type assays.
[00:15:04] Then we’ve got things like these fluorescence distribution sorts of
assays and this is where we look for translocation of proteins from the membrane to the cytosol or the cytosol into the nucleus. We can look at DNA damage by looking for foci in a nuclei and we can also look for co‐localization. So if we can label two sets of structures within the cell fluorescently, we can see how they co‐localize.
Then we’ve got the next sort of set of two which perhaps ones which
are becoming more common now. The first one is cell behavior over
8
time. So this is now becoming more and more important particularly in stem cell biology is to actually look at cells using time lapse type systems and also high content imaging systems can do this now. It’s used to actually get real time measurements of things like the cell division times, the lineage tracing, whether the cells are migrating, and again shape changes based on the imaging.
Then finally another aspect which is becoming more and more
common now is to look at what we term higher‐order structures and this is where we combine various features that we’ve imaged together to create larger objects that you might be imaging. So the simplest one is that we create virtual cells within the software. So we tell the software that we need a nucleus and we tell we’re going to use a cytosol and we tell the software that those tissue be linked together and then we can ask questions about the relationship between fluorescence. Within those two compartments if we combine lots of cells together particularly with this is pretty relevant for pluripotent stem cells, you get colonies and you can ask about what the marker expression is across the whole colony. This has now been extended to embryos such as zebrafish embryos and things like that and tissue distribution by looking at slides as tissue stained slides.
Slide 21 So what factors do you need to think about when you’re doing these
assays? Remember, these are imaging based assays so they go into a microscope. So one of the problems that we encounter of course is that typically people will grow cells in tissue culture plates for example and these can vary greatly in their ability to be imaged accurately and easily. So 6‐well plates can really – very, very thick plastic actually compared with coverslips for example and so you may find you have problems with sensitivity in using those sorts of plates so you have to change to either much thinner base plates or change completely to using coverslips.
The resolution required, you need to think about. As you use higher
and higher NA lenses, they become more and more difficult to use with standard tissue culture plastic just because of the thickness and because of the way the plastic is made. It’s not very even and things like that. So again, you may need to think about slides.
The well size, this is one that most people don’t really think about
but can you really see enough of what you need to see in one well? You know, if the well size is small and you need to look at lots and
9
lots of cells, you may not have enough cells in one particular well. In the case of human ES cells, colonies, it becomes a problem that we need to get enough colonies in our well to be able to see something meaningful.
Then the caveat of that, of course the counter thing to that is of
course remember that, you know, different size magnifications it will take you longer to cover a particular area of a well or particularly a number of wells so that can slow the assay down and that maybe a factor for you.
Then the final thing you have to consider is of course the number of
colors. Remember that typically we can only deal with four colors, which is in contrast with flow cytometry, which can deal with more and also for certain fluorescent reporters and things they may be very, very weak and you may have to use specialized filter sets, which you do need to think about before you start these experiments.
Slide 22 So as I mentioned, there are some pros and cons regarding when
you compare with flow cytometry. So in the acquisition side, the first really big, first major difference you’ll notice is the throughput. The flow cytometers are very, very good at getting single cell data from large numbers of cells. The high content analysis type systems are much better for large numbers of conditions with a sort of moderate number of cells. So that’s the sort of thing you need to think about there.
As I’ve mentioned, the parameters, the flow cytometers have a huge
color part they can see. It’s typically up to 12, it can go even higher depending on the machine configuration. For microscope systems it’s typical just four.
The sensitivity again as mentioned before, the flow cytometers are
very, very sensitive instruments because of the way the optics are arranged and the type of detection they use. The high content analysis systems tend to be less sensitive in part because it’s going through a lot of glass in the objectives, in part because of the plates people use and the fact they’re using CCD detection. Having said that, the machines are getting more and more sensitive due to better camera technology and better light technologies. So in theory, they should become more sensitive but you do have to watch that.
10
Obviously, subcellular imaging then apart from the imaging flow cytometers, flow cytometers don’t let you do subcellular analysis whereas high content analysis that’s really routine for this type of analysis.
[00:20:17] Okay. On the data analysis side, the flow cytometers again with
single data, it collects single cell data very, very easily and this is for all systems that you will use it will be very, very easy to get this sort of single cell data. With the high content analysis because the cells are stuck down and next to each other, you have to do image analysis to separate them into single cells first of all. The major problem there is of course some cells will pile up on each other where you may seeded them too densely and then that causes quite a lot of problems when we start to do the actual analysis.
Another factor which again as I mentioned is becoming more
fashionable to do is time series or time lapse type things and of course on flow cytometry, you can only really do that by sampling but on high content analysis systems now that’s becoming more routine. The systems can be supplied with CO2, humidified CO2 systems and heated chambers and the software will enable you to screen the time lapse images together to get that sort of data really quite easily now.
Of course, the final thing, which is again the major thing about high
content analysis, is the cell‐cell relations are lost with flow cytometry. So in high content analysis, we preserve all that. We know exactly where we got the information from so those relationships can be reconstructed.
Slide 23 Okay. So what’s the actual process that we go through? So the
process is summarized here. We acquire the image. We do what’s called segmentation. Segmentation is where we pull out the features we’re interested in from the image and this is by sophisticated image analysis algorithms. Then what we do is we then have to tell the software what the features are and how we wanted to handle it, which is called feature extraction. We then put some parameters into the software to tell it how we want to classify those features.
The example that we got here, just the most simple example is
you’ve got some Hoechst‐stained nuclei from human ES cells so you can see these colonies in this picture. They’ve been segmented. If we then do some methodical treatment to that segmentation, we can
11
then dilate where we think the nuclei are and of course that will show us where the colonies are because it all merge together. Then what we do is we just tell the software well the colonies are the big blobs, everything else as you go smaller is not the colonies. That’s what you see in the final picture there where the colonies have been labeled in green and the rest of the cells have been labeled in red and that’s how we then would extract where the colonies are from these images.
Slide 24 So how do we do that extraction, that segmentation extraction or at
least what does it look like? So we’ve got some examples in the next few slides, which will just illustrate to you the types of segmentation you can do. So on the left here, we’ve got nuclei segmentation and what will typically happen here is we will apply the segmentation algorithm and then we have to try and separate the nuclei using other algorithms to separate them out from each of the – it’s called clump breaking or anything like this. So that’s because of they’re very close to each other in some situations.
On the right‐hand side, you’ve got mitochondrial segmentation,
which is of course they’re really quite tiny features. For this, you would have to use high NA lenses. You need a nice dye for this and then there are algorithms, which can handle these types of small vesicular features. They are different from the ones which do the nuclei segmentation, but most software will have various algorithms which can be applied to different features.
Slide 25 We’ve got for the whole cell sort of the cytosolic level. This is just
very, very simply you can label the cytosol with various dyes as Dr. Telford alluded to there or with fluorescent proteins and it becomes relatively simple then to segment the cytosol, tell the software that’s the cytosol and away you go. Then finally sort of larger scale features again as I mentioned is the colonies and things like this, which is caused when we merge the nuclei that we segmented from the original Hoechst stain picture and this gives us where the colonies are. The red dots in this or the red features in this picture here in fact are fibroblasts which we use as feeder the cells, which are quite easily separable from the colonies.
Slide 26 Okay. So what’s the sorts of measures we can do? Well it’s really
anything you can think of that you could measure from an image
12
once you’ve extracted the feature from it. So we get all sorts of things from images once we started this process going. Again, in this example of human ES cell colonies, which have been stained with Hoechst, have been stained with pluripotency marker with SSEA 3, we can get the number of cells in the colony, the number of cells positive for the SSEA3, how far apart the nuclei are., and then going up to the colony level how many colonies are in the well, what the shape is, what the area is, and also the spatial relationship between the colonies and things like the number of positive cells in the colonies. So you can really get a lot, vast amounts of information about what this culture is really like and remember all of this is the spatial information in particular was lost with flow cytometry so we tend to use these things in conjunction with each other.
[00:25:34] Slide 27 This is an example of what the data would come out like eventually.
So we’ve done exactly the same thing here but we’ve got an additional marker which is OCT4 another pluripotency marker. As you can see by going through all this analysis process, you can get flow cytometric like data, i.e., population histograms after these images either as univariate plots or bivariate plots. You can simulate setting gates just like you would in a flow cytometer and you can get numbers that are proportionate to each fraction that you’ve identified.
As Dr. Telford alluded to the advantage is we can go back to look at
the individual cells in these images because the software records where it’s made all these images, where it’s made all this analyses from.
Slide 28 This is another example just to show you how you can get this flow
cytometry like data. This is stained for BrDU and the DNA stain and you get this sort of classical horseshoe plot to show the cell cycle phases, which is similar to what we would see with a flow cytometer. So it’s really quite remarkable that you can actually get this out of really quite messy and complex images.
Slide 29 So I’ll finish there and it just remains for me thank various people in
various labs, which help us do all this sort of stuff because we actually make reports and all sorts of things to actually test these
13
systems out so it’s actually quite a complex exercise and I’ll stop there.
Slide 30 Sean Sanders: Wonderful. Thank you so much, Dr. Gokhale, and thank you very
much for joining us even though you couldn’t make it into the studio. It’s great to have you on the line.
Our final speaker for this webinar is Dr. Liz Roquemore. Dr.
Roquemore’s training is in diverse aspects of intracellular protein regulation, membrane protein trafficking, and cell phenotypes. She is now the technology manager for cell applications within the Cell Technologies Division of GE Healthcare Life Sciences and has played a leading role in the development and validation of cell lines, reagents, assays, and imaging tools for research and drug discovery. Her major focus area for her work has been the application of high throughput microimaging and analysis technologies for cell biology research and drug development, most recently investigating the combined use of stem cell‐derived model systems and high‐content analysis techniques to enable earlier predictive toxicity testing. Welcome, Dr. Roquemore.
Slide 31 Thank you very, a pleasure to be here. So after that great overview
of HCA, I’d like to take a step back and just give you sort of an overview of image cytometry and the range of instrumentation that’s available for doing image cytometry and also the types of applications that those platforms are best suited to.
Slide 32 So image cytometry in its broadest sense can be defined as the
process of extracting and making sense of cytometric data obtained from images of cells. So as alluded to in the previous talks, those images can be obtained in a variety of ways with a variety of systems, but the emphasis is not so much on the images themselves in image cytometry but on the data that we can extract from those cells and the knowledge that we can gain from that process.
Slide 33 Image cytometry has four basic components. Those include the
cellular samples of course that we’re working with, the probes and sensors that we add to the cells to understand their function phenotype, the imaging platforms that we’re working with, and not least of all the image analysis software which allows us to turn those
14
images into data. All four of those components are continually evolving together so that advances in any one of those areas propels advances in the others. So we’re seeing a lot of very exciting developments now in each of these four areas as image cytometry progresses.
Slide 34 So why imaging as an approach to cytometry? Well I think the two
previous speakers have summarized very nicely the fact that with image cytometry, we can gain quite a lot of information about morphology, structure, kinetics and position and location of cells and also the orientation of cells and groups of cells that we may be studying.
Also as a lot of the higher content imaging systems can process many
samples in parallel, many samples very quickly, we can do higher throughput studies, larger scale studies all the while collecting very comprehensive data from the cell population and building up unique fingerprints as to the cell phenotype.
[00:30:13] Now we’re also seeing the emergence of more convenient image
cytometry systems, which are more compact, more affordable, more accessible to the members of the laboratory and they can be located throughout the lab, and you don’t necessarily need an expert to run those systems or any extensive training. So image cytometers really fall on a spectrum from those which focus on depth and breadth of information that we can gain and the others that are specialized more for ease of use and accessibility.
Slide 35 So let’s take an example form the depth and breadth end of that
spectrum and we’ll look at cell cycle analysis as an example. Slide 36 So perhaps one of the simplest ways of looking at cell cycle phase is
to do DNA content analysis and when we’re working with adherent cells, it really makes a lot of sense to go for an image based cytometry to do that because we don’t need to disturb the cells to be able to quantify the DNA content.
Slide 37 Doing that, we can get results, which are strikingly similar to the
results that we would get with flow cytometry. So here for example,
15
you can see that we’re getting very similar cell cycle phase profiles but there are two main differences. The first is that because we’re working with an imaging technology, we can process the samples very quickly and also because we’re not having to remove the cells from the dish or undergo any centrifugation wash steps, the whole process is taking us a lot less time on a high content imager for these adherent cell types.
The second big difference is that not only do we get these cell cycle
phase distributions from the intensity information, but we have a lot of morphological information that we get virtually for free with no extra time or effort.
Slide 38 So here you can see for example that when we treat with mitomycin
C, we’re getting a dramatic increase in the nuclear size. We can follow that for every cell in every image and that can give us more confidence in the conclusions that we draw from our cell cycle phase analysis, but it also can lead to new insights into the function and the mechanism of action of our drugs.
Slide 39 We can add a second sensor as shown in the previous talk to further
delineate the S‐phase cells. In this case, we’re looking again at incorporation of bromodeoxyuridine and we’re getting that classic horseshoe‐shaped distribution of the cells.
Slide 40 But things get really interesting if we get a third sensor to the mix.
Here, this is something that we could only do with an image‐based platform because this is a GFP sensor, which marks the cell cycle phase position of the cell by not only its intensity but the position of this probe within the cell. So now, we see something very interesting here. So we’ve again got that classic horseshoe shaped distribution of our control cells in blue and our cells treated with a test compound in red. You can see that the test compound is causing that horseshoe‐shaped plot to shift to the right, but now we’ve got a third dimension added to this plot and that’s represented by the diameter of the spheres that are plotted here. Those diameter of the spheres are telling us about the cell cycle phase position as reported by this GFP reporter.
What we find is that even though the cells on the right which are 8n
are in the position that you’d expect G2 cells to be, they actually
16
have characteristics of G1 phase cells. So by using this GFP reporter, we’ve learned a little bit more about the mechanism of action of our compound, which happens to be where our kinase inhibitor and it’s causing the cells to undergo a process called endoreduplication where the nuclei divide but the cells cannot undergo cytokinesis.
Slide 41 So I hope that gives you a flavor of some of the many types of things
you can do with an image cytometer that you maybe you couldn’t do with other technologies. There are some emerging trends in the instruments that are available to do this and some of those include a more complete solution. So increasingly, we’re seeing systems which take us all the way from acquisition through to analysis and even interpretation of our results seamlessly. We’re also seeing more fluorescence‐based kits and assays available that can really cut down on our assay development times.
Another thing that we’re seeing is that the systems are all getting
quite fast and they’re able to collect much higher quality images than ever before. That’s very important because the quality of the data that we get from HCA is only as good as the images we start with.
A third trend that we’re seeing is towards more flexibility with
confocality. So instead of being locked in for example to a particular pinhole sized confocal aperture, we’re now seeing systems which give us variable aperture and that can really give us more flexibility in terms of the applications that we can cover. All of these improvements are being made possible by new technologies being incorporated into the systems including scientific grade CMOS cameras, diode lasers and LED technology.
[00:35:20] Slide 42 But what about the more routine assays that we do every day in the
laboratory like counting cells and doing cell health and phenotype analysis? For those systems, maybe high content analysis is a little bit of an overkill but we still want to get some of the benefits of imaging. There, we might want to turn to systems, which are more focused on ease of use and accessibility.
Slide 43 A good example there is cell count and viability. So this is an assay
that we do every day in the lab. It’s very simple and we really want
17
to be able to do it anywhere, anytime and not have to turn to an expert to do it. So typically we’ll run a two‐color assay like this one where we’re marking the total cell population with a red dye and the dead cell population with a green dye and in this case we were running it on a Cytell Image Cytometer and you can see that we’re able to get very familiar results. We can set our thresholds to separate the live from the dead cells and we’ve got a selection of gating tools so that we can do further subpopulation analysis.
Slide 44 Then we can generate dose response curves from our data and
here’s an example of a camptothecin dose response curve and its effect on cell viability. In case you’re wondering what that little disc is in the upper right‐hand corner, that is the sample holder for Cytell. It can hold eight different sample cartridges. So we’d simply put a small ‐‐ for this dose response curve, we just put a small volume of sample into each of those eight cartridges and we get the results for the entire dose response curve in about two and a half minutes.
Now these are the results with Jurkat cells, which are a suspension
cell type. But what we find is that whether we’re working with suspension cells or adherence cells, we’re getting results which are strikingly comparable to other image cytometers.
Slide 45 Then my last example is one where we were working with peripheral
blood monocytes and we were developing an enrichment procedure for T‐cells and this is another one where an image cytometer came in handy. So here for example, you can see our results are showing us that our cells are about 96% CD3 positives. So this was a good verification for us that our T‐cell enrichment process was working well. The other thing that we wanted to know about was the ratio of CD4 helper cells to CD8 cytotoxic T‐cells. That’s typically about 1.5 to 1 in the average individual and here you can see our results that we got with Cytell showed we had 1.5 ratio, which corresponded very well to published results.
Another thing is that we wanted to migrate this assay from flow
cytometry, which we do quite a lot of in the laboratory, to an image based cytometer so that we could handle this routine assay a little bit more readily within the lab. So we did a little bit of benchmarking and here you can see that we’ve got strikingly comparable results between the Cytell Image Cytometer and the flow cytometer that we had in our laboratory.
18
Slide 46 So what are the things that we had to consider when we were
thinking about doing these more routine assays on an image cytometer? Well of course, we thought about the level of expertise available in the lab and where we would like this instrument to be located and we’re finding that some of these more value image cytometers can be located anywhere and don’t require a lot of expertise.
Another thing to consider is whether we go with predeveloped
acquisition and analysis protocol or user‐defined ones. We like a mixture of both because the predeveloped ones can save us time and expertise but the freedom to create your own can give you some flexibility.
Speaking of flexibility, it’s also good to have flexibility for the various
dyes so that we’re not locked into any particular assays. If we’re working with an open system like this, we need to think about the number of excitation and emission channels that are going to be available.
Last but not least, speed is something that needs to be considered.
So when we want to think about the speed all the way from the time we load the sample to the time we get the results, and if we can run multiple samples in parallel that can really save us time. Another thing to remember is about the hidden cost, time penalties that might be associated. So for example if a system needs to have a lot of setup time or if there’s calibration involved or wash steps, those can be time penalties that maybe you hadn’t counted upon.
Slide 47 So just to summarize, I think in our experience we found that image
cytometry and flow cytometry are very complementary. One is not necessarily going to replace the other but with image cytometry, we can get quite a lot of additional morphological information. We can use adherent cells or suspension cells and increasingly the technology to do that is becoming easier and more accessible.
[00:40:03] Now we’re in a state where we’ve got quite a lot of instruments to
choose from and so we can actually afford to match the image cytometry solution to our needs rather than being driven by the instrumentation in our assay choices, and that’s really a smart way to go.
19
So for detailed phenotyping and functional studies and screens,
we’re finding HCA has quite a lot to offer in terms of the power and flexibility that we have. For the more routine assays, I think it’s really worth looking at some of these value image cytometers that really can bring that capability right to your bench top without a lot of added expertise required.
Slide 48 So finally, just to show you some of the image cytometry solutions
available from GE healthcare that we’ve used to generate the data in this presentation. At the bottom I’ve got the IN Cell Analyzer 6000 which is our confocal version of the high content imager, it’s got variable aperture technology, the IN Cell Analyzer 2000 which is our very flexible wide‐field system. Our most recent introduction is the Cytell Image Cytometer, which is quite compact. It’s got two lasers and four emission channels and really does allow us to do quite a lot of the routine assays everywhere in the lab.
Slide 49 So that brings me to the end of the talk and I just like to thank
people for their attention and hand back over to Sean. Sean Sanders: Great. Thank you so much, Dr. Roquemore, and thank you to all of
our speakers for the wonderful presentation. Slide 50 We’re going to move right on to the questions submitted by our
online viewers. Just a quick reminder to those watching us live that you can still submit your questions by typing them into the text box and clicking the submit button. If you don’t see the box on your screen, click the red Q&A widget and it should appear.
So we’ve got a lot of questions so I’m going to try knock through as
many of them as possible. But the first question I’m going to ask is about the percentage of assays that are flow versus HCA in your experience. So I know all of you have done both of these so maybe you can talk to that in your particular laboratory, Dr. Telford?
Dr. Bill Telford: Sure. Well I run a core facility at the National Cancer Institute so we
probably have about 80% of our work being flow cytometry and the other 20% being image cytometry. But the image cytometry tends to be done for very specific purposes where the imagery is really critical. We do a lot of apoptosis analysis on the image cytometer
20
because you want the morphological data along with the fluorescence data and it’s very powerful for that purpose.
We have some other interesting applications too. We do a lot of cell‐
cell based assays where we want to look at cell‐cell interactions and that’s something again where you’re not going to get that information out of traditional flow in the stream. You’ve got to have the cell sitting on a dish to collect that data. We have people who do very small numbers of cells where they’ll just dab them on a plate and allow them to settle. We have applications where people want to analyze their GFP expression in a 96‐well plate, but they don’t want to discard the cells. They want to put them back in an incubator and keep running them. With these image cytometers, with many of them, you can put the plate with the lid on, on the instrument, scan it, and then put it back in the incubator. Again, you haven’t destroyed your cells as part of the analysis. So a lot of specialty applications like that where flow cytometry really doesn’t provide the advantages that image cytometry does.
Sean Sanders: Great. Dr. Roquemore? Dr. Liz Roquemore: Well I think our experience is very similar to yours in that we
probably have about 30% of the people in the lab doing flow cytometry and then maybe 70% of the assays would be high content analysis. We do a lot of cell production and I think flow cytometry is very useful there. But increasingly we’re finding these bench top image cytometers can really get the job done quickly. We don’t need to have a lot of trained experts to do it and so we’re getting those being used more and more often. Then on the high content analysis side, we’re finding that we can get really detailed cellular phenotype data from the HCA, which we just couldn’t get by any other means and that’s really breaking new ground in terms of understanding how compounds act on a cell and predicting their toxicology, toxicity for example.
Sean Sanders: Great. Dr. Gokhale? Dr. Paul Gokhale: Yeah it’s very similar actually to Dr. Telford. It’s about 80%, 20% and
it’s for very similar reasons. It’s where we need morphological information, we will do the in situ high content assay or for time lapse imaging.
Sean Sanders: Uh‐hum. Excellent.
21
Dr. Paul Gokhale: For the rest, we do flow cytometry. Sean Sanders: Great. So the next question I’m going to ask, there’s been a couple of
questions about resolution and size limit for flow and image cytometry and I know that one of you did show a slide looking at the mitochondria. So really, what is the resolution of image cytometry current? What can you get down to? Maybe Dr. Roquemore, we’ll start with you.
Dr. Liz Roquemore: I think with the high content systems particularly if you’re going for
the confocal ones, we can go quite small down to the micrometer size.
[00:45:02] Sean Sanders: All right. Dr. Liz Roquemore: So we can see small things like mitochondria. We get great detail
from the cells. On some of the more bench top image cytometers, for Cytell for example the size range would be from 5 microns up to about 25 microns.
Sean Sanders: Okay. Dr. Telford? Dr. Bill Telford: Yeah. Again, it really varies depending on the system, although some
systems have some flexibility. A lot of the data I showed in my talk was from the Compycyte iCys system and it can go down to I believe 0.5 micron resolution. So you’re not visualizing individual organelles at that level but you can look at translocation from the cytoplasm to the nucleus. You can look at fluorescence polarity if the fluorescence is greater on one side of the cell or another and you can also vary that resolution. So the higher the resolution, the slower the scan. If you need to scan 96‐well plates for viability, you can scan them but a very low resolution like a 5 or 10‐micron resolution and do a 96‐well plate in 15 minutes.
Sean Sanders: Uh‐hum. Dr. Bill Telford: And the you can do the converse situation where you need to look at
individual cells and look at subcellular detail and the scans can be much longer than that.
Sean Sanders: Great. Dr. Gokhale, how about in your experience?
22
Dr. Paul Gokhale: It’s typically down to mitochondrial size to be honest with the much smaller ‐‐you’re starting to use very, very specialized optics done. I mean you can get 60 times and a hundred times air lenses for example and water‐immersion on these systems. But as I alluded to in my talk, it becomes progressively more difficult to maintain focus on things in an automated system because you got other factors affecting you like autofluorescence caused by the plastic ware or the fact the plastic ware is not made flat. So you then start to really need to be thinking about systems, which look at coverslips and then maybe more of a hybrid system. You can now get software for the conventional microscopes which behaves much more like a high content system where you can take multiple fields in a well or on a slide. So you start to think about systems like that where you’re using proper high confocal optics and things so.
Sean Sanders: Great. Excellent. So I’m going to come to you, Dr. Telford, for a more
specific question about stem cells. We have a couple of questions on that here. This person asks what markers and staining protocols you use to identify your stem cells and how you manage quality control?
Dr. Bill Telford: Well we certainly – you know, most of our stem cell analysis is in the
flow cytometry platform, although we had done some image cytometry as well. So we use a wide variety of cell surface markers. Most of our work is murine so we’ll look at [c‐Kit+, Sca‐1. We’ll look at the SLAM markers, CD150, 244, 48. We still use Hoechst side population quite a bit. This is an older technique. It was developed by Peggy Gooddell back in the mid‐‘90s, but it’s proven to be relatively resilient in the sense that it does – while certainly not universal it does appear in many mammalian stem cell hematopoietic and non‐hematopoietic populations.
Sean Sanders: Uh‐hum. Dr. Bill Telford: So we still include that in our analysis and it’s actually quite
compatible with immunophenotyping so we don’t lose anything if we add in the Hoechst red and Hoechst blue or dicycle red and blue. I think probably Dr. Gokhale can speak more to the imaging aspects of stem cells than we can.
Sean Sanders: Sure. Sure. Dr. Gokhale? Dr. Paul Gokhale: Yeah. I mean we actually use the same antibodies we would use on
flow cytometers, although of course from these antigens and things we discover, the image cytometer didn’t really exist so it’s exactly
23
the same antibodies. So it’s very… the stains and everything are really very similar apart from the trypsinization of the cells to what we would use for flow cytometers. So and you have the additional thing that we would coat Hoechst in with thick cells just to locate the cell so very, very similar.
With regards to quality control, all the antibodies are titered against
cells that we’re using to check that they are in fact at the correct place in the titration curve and the same for the secondaries. Also, we do have cell lines that we know express the markers that we use that can be used as positive control as well. So we tend to find that gives us a bit more consistency if we include those controls.
Sean Sanders: Uh‐hum. Now stem cells tend to be rather delicate cells and flow
cytometry can be a little bit harsh as far as conditions are concerned so I’m guessing that maybe the HCA systems might be a little bit better for looking at stem cells? So maybe Dr. Gokhale, can you comment on that?
Dr. Paul Gokhale: Well yes. Well particularly human pluripotent cells, like ES cells and
human embryonic stem cells, do not like being on their own. So when you trypsinize them, you’ll start to induce cell death in a large proportion of them in theory. So whilst you can analyze them on a traditional flow cytometer, you know, if you just put in and so you don’t care the cells die afterwards, if you want to recover them with the flow sorter, I’m afraid you’re going to get quite high cell losses. We typically factor it about 50% cell loss.
[00:50:26] The other factor when going through a flow sorters that we found is
that human embryonic stem cells have very little cytosol so they don’t like going through these machines at very high speeds because they can’t endure shearing forces which can rip them apart. So we have to turn all the pressures down and actually sort at a slower rate than you might be able to in some of the cell types. Yeah, it’s just one of those things. The mouse cells clone a lot better. They’re actually better at handling this but for some reason human embryonic stem cells just don’t like being on their own.
Sean Sanders: Uh‐hum. So Dr. Telford, I know you have some experience with the
use of flow. Dr. Bill Telford: Yeah. We’ve observed exactly the same thing. Really the only
strategy you can do is turn down the pressure on your instrument. Use a larger nozzle. Basically go back to the pressures that we used
24
15, 20 years ago for sorting all cells to try to, you know, minimize the damage. Stem cells, particularly human stem cells they’re like dendritic cells and apoptotic cells, they tend to be very, very fragile and they don’t tend to deal with the high differential pressures in stream and air sorters very well. So really just turn down the pressure and maximize the nozzle size.
Sean Sanders: Right. Dr. Bill Telford: If you can. Sean Sanders: Dr. Roquemore, any comments on stem cells? Dr. Liz Roquemore: Yes. We work with stem cells quite a lot in the lab and I think our
experience is similar to the other two speakers really that the cells like to be together. They don’t like a lot of shear forces and so a lot of time we are using the high content system to characterize those cells. It gives them time to recover on the dish, makes sure that they’re expressing everything they should be expressing.
Sean Sanders: Uh‐hum. Dr. Liz Roquemore: And they’re just generally happier cells then when we go to image
them. Sean Sanders: Right. So the next question I have is the application of
immunocytometry in microbiology and I’m not sure which of the speakers have much experience but maybe Dr. Roquemore, are you aware of anyone that’s using it for bacteria –
Dr. Liz Roquemore: We are aware of some applications where people are using high
content for very small organisms like yeast and bacteria but you don’t hear about that a lot.
Sean Sanders: Uh‐hum. Dr. Liz Roquemore: So I know that the resolution is there to do it but I’m not – you know,
you don’t hear about a lot of applications in that area. Sean Sanders: Right. Dr. Liz Roquemore: Particularly because I think people are looking for things they can do
at high speed screening.
25
Sean Sanders: Okay. So the next question, the viewer seems very impressed by the data. He says it seems that the assays are great, there’s no need ‐‐ and it doesn’t seem there’s a need for an expert to be involved. But is this the truth, is this, the high content systems, are they something that you can set up and somebody maybe with less experience can use? Dr. Telford, you want to try this?
Dr. Bill Telford: You know, what we tell our users with the image cytometry is that
the sample is 2/3 of the battle because unlike flow cytometry where you’re triggering on individual cells and most of your trash and debris are flying away and you’re not seeing them, with imaging, you’re seeing everything. You’re seeing all the garbage and everything else. So you really need to do a very high quality sample preparation and what we tell our investigators is the same techniques and care that you apply to your microscopy should be applied to image cytometry as well because the same problems that you’ll have with microscopy will also occur with image cytometry too.
You choose fluorochromes that don’t bleach easily. A lot of these
systems have lamp or laser dwell times in the seconds where a typical flow cytometer illuminates that the cell for about a microsecond. So we like to use some of the newer fluorinated, sulfonated low molecular weight probes like the Alexa Fluor dyes work rather well, Quantum dots. Quantum nanoparticles work very well. Take the same precautions we would from microscopy, use reagents that will prevent photobleaching. Anything you can do to maximize the intensity of your fluorescence and to keep your samples as clean as possible should be applied here.
Sean Sanders: Uh‐hum. Great. Dr. Gokhale, I’ve got a question for you that came in
during your presentation about the software packages that you use when you’re doing your analysis. Are these available commercially or are these something that’s being developed in your lab?
Dr. Paul Gokhale: Well the images, the thing that I showed are actually from
commercial packages, which is the GE developer toolbox. Sean Sanders: Uh‐hum. Dr. Paul Gokhale: There are other commercial packages out there, which will do similar
things and you really do need to check them out if they will do what you want them to do with the… I would strongly recommend that you test it on real images of your biology that you’re trying to look at
26
because you can have all sorts of problems trying to segment images with certain packages depending on how they do it.
[00:55:09] For the time lapse imaging, we do develop our own software for that
but that’s because it’s using phase contrast imaging so it’s using very sophisticated image analysis techniques to do that so that’s not commercially available. But I fully expect that sort of systems to be available in the future actually. It’s becoming more and more common to incorporate that sort of analysis into these software packages.
Sean Sanders: Uh‐hum. Excellent. So a question now from somebody who’s
obviously looking to purchase a high content system and they’re interested in what you would say are the most important features to consider when you’re looking at an instrument. Dr. Roquemore, I know you might be a little bit biased towards the GE machines but maybe you can all talk about the things that you look for. So we’ll start with you, Dr. Roquemore.
Dr. Liz Roquemore: Yeah. I’ll try to be as unbiased as possible. I have been doing
microscopy for a number of years and – Sean Sanders: Right. Dr. Liz Roquemore: ‐‐ used a lot of different systems. I think key when thinking about a
system is going to be the flexibility because you know you’re investing quite a lot in a system and you want to make sure that it’s going to be able to do the applications that you’re doing now and the things that maybe are unforeseeable that you want to do in the future. Another thing has got to be image quality. I think, you know, you want to make sure you got the best optics that are available to generate those images because the data that you get really is only going to be as good as the images. The third thing I would say is speed. If you’re turning to a high content system, it’s not like a research grade microscope. You’re investing in one so that you can get a lot of data from many different samples in order to be able to get that high content information so speed is really important. So those are three key things that I would look for.
Sean Sanders: Right. Dr. Telford? Dr. Bill Telford: Yeah. I would also think about some of the ways, some of the
internal aspects of the instrument whether it’s for example laser based or lamp based. Most image cytometer systems either use
27
lasers where they raster an image or use some of their line scanning or they use a lamp like a xenon lamp to excite the sample. On the downstream detection, they can use sometimes photomultiplier tubes. CCD cameras and chips now are becoming more common in some systems. As far as the laser‐based systems, I think you’re going to have better sensitivity. You may have better edge‐to‐edge uniformity of the sample than you will with the lamp‐based systems. But laser systems tend to be slower and lamp‐based systems can often be very, very rapid, have very high throughput. With the xenon lamp, you can also filter off any bandwidth you want really from the violet all the way to up to the red. So there’s a certain amount of flexibility in excitation out there.
But certainly some of the systems that we’ve talked about today,
we’ve talked about the Compycyte iCys, the GE IN Cell Systems, the PerkinElmer systems. These are all being used very actively in laboratories now and we’ve tested most of them and they’re all very, very good at what they do. So they’re all worth considering. Just think about what your application is going to be and whether sensitivity is your primary concern, is high throughput your primary concern, high versus low resolution and so forth.
Sean Sanders: Uh‐hum. Great. Dr. Gokhale, do you have anything to add? Dr. Paul Gokhale: Well there’s a couple of things, some very, very sort of practical
aspects is also focus systems. So with HCA systems one of the things that you want it to is go from field to field and be able to focus as it goes from well to well. You really got to have autofocus systems that can work very, very well. You know, so you must test that out with whatever plates or whatever you’re planning to use. The other thing is the software, will it do the things that you want it to do and is it easy to learn and stuff like that. You know, you want to be concentrating on looking at the biology and understanding the biology not having to, you know, relearn programming or something, you know. So I think those are the additional things. The points that the others speakers made though are excellent sort of guides to what you should look for.
Sean Sanders: Fantastic. Well we’re at the top of the hour but I’m going to shoot
one more question to you that maybe you can answer very briefly in 30 seconds. That is where do you see the field of high content analysis moving in the next five to ten years or what would you like to see that will really drive your research? So we’ll start with you, Dr. Telford.
28
Dr. Bill Telford: What I’d like to see is all flow cytometers have imaging where
imaging will become a parameter just like forward scatter or fluorescence is a parameter. I think you’re seeing it in the Amnis Image Stream. It’s sort of the forerunner of this, which is currently the one system that will do in‐stream imaging. I think all the major manufacturers are looking at that very closely and I would very much like to see a picture of the cell be a parameter and all the subsequent intracellular data that you can pull out of that be a parameter just like fluorescence or forward scatter is.
[01:00:14] I think the slide‐based systems are quite well developed now. I think
we’re going to see increases in speed and resolution but that’s another direction that has proven to be very productive in biomedical sciences, and I think we’ll continue.
Sean Sanders: Uh‐hum. Dr. Gokhale, now about you? Dr. Paul Gokhale: More colors will be useful. And when we compare it with flow
cytometers, at the moment we’re quite limited which is partly reagents so it’s not really the manufacturer’s fault. But it would be good to have systems which could handle more colors if we could actually have the – if we have the reagents to do it.
Sean Sanders: Right. Great. And Dr. Roquemore, last word for you. Dr. Liz Roquemore: I think we will see quite a lot of good developments in this area but
one of the main things I’d like to see is the systems continually become easier to use. So the emphasis is no longer on being an expert to use the instrument but putting the scientist is then freed up to put the effort in to developing the assay and handling the cells properly and the instrument is just there and does its job. And also I think we will see great developments on the image analysis side of things so that not only will this software be analyzing the data for you but it will be interpreting it for you and helping you process all that great amount of high content data.
Sean Sanders: Fantastic. I just wanted to mention very briefly before we close out
the webinar, I know some of you did have some trouble downloading the slide deck. We will make sure that that is available on the on‐demand webinar so come back any time in about 48 hours to look for the on‐demand. You will get an email alerting you to that, the availability of that archive.
Slide 51
29
But we are unfortunately out of time now for this webinar so on behalf of myself and our viewing audience, I wanted to thank our speakers very much for being with us today: Dr. Bill Telford from the NIH, Dr. Liz Roquemore from GE Healthcare, and Dr. Paul Gokhale on the phone from the University of Sheffield.
Please go to the URL now at the bottom of your slide viewer to learn
more about resources related to today’s discussion, and look out for more webinars from Science available at webinar.sciencemag.org. This webinar will be made available again as an on‐demand presentation within approximately 24 to 48 hours from now.
We'd love to know what you thought of the webinar, send us an
email at the address now up in your slide viewer, [email protected]. Again, thank you to our wonderful panel and to GE Healthcare for
their kind sponsorship of today's educational seminar. Goodbye. [01:02:40] End of Audio